Oral TIX100 protects against obesity‐associated glucose intolerance and diet‐induced adiposity
Thus, TIX100 may provide a novel, oral therapy for T2D that targets underlying disease pathology including islet cell dysfunction and hyperglucagonemia and promotes metabolic health and weight control without aggressive weight loss.
Authors
- Anath Shalev (ORCID: https://orcid.org/0000-0003-2869-7228)
- Junqin Chen (ORCID: https://orcid.org/0000-0003-2653-1814)
- Guanlan Xu (ORCID: https://orcid.org/0000-0002-4391-5046)
- Jing Gu (ORCID: https://orcid.org/0000-0001-5903-0309)
- SeongHo Jo
Institutions
- University of Alabama at Birmingham (US)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-02-03
- DOI
- https://doi.org/10.1111/dom.16223
- Citations
- 2
- Primary Topic
- GDF15 and Related Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 3.34
Funders
- National Institute of Diabetes and Digestive and Kidney Diseases